Angiogenesis inhibitors in the treatment of lung cancer

Lung Cancer

Volumn 34, Issue SUPPL. 3, 2001, Pages 81-89

  Shepherd, Frances A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiogenesis inhibitors; Non small cell lung cancer; Small cell lung cancer

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; AE 941; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBOPLATIN; ENDOSTATIN; GROWTH FACTOR; INTERFERON; MARIMASTAT; METALLOPROTEINASE INHIBITOR; NAVELBINE; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; PRINOMASTAT; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; REBIMASTAT; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERFERON; TANOMASTAT; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; DRUG ACTIVITY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS;

EID: 0035203484     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00377-4     Document Type: Conference Paper

References (62)

1. Current approaches to targeting cancer using anti-angiogenesis therapies
2. Endothelial proliferation in tumors and normal tissues: continuous labeling studies
3. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer
4. Tumor angiogenesis: past, present and the near future
5. Angiogenesis and non-small cell lung cancer
6. Tumor angiogenesis: therapeutic implications
7. Interferon α-2A therapy for life-threatening hemangiomas of infancy
8. A prospective randomized trial of two dose levels of interferon-alpha with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection
9. Natural interferon alfa as maintenance for small cell lung cancer
10. Phase III trial of recombinant interferon gamma in complete responders with small cell lung cancer
11. Role of recombinant interferon alfa-2a maintenance in patients with limited stage small cell lung cancer: a Southwest Oncology Group study
12. α-Interferon (alfa-ifn) as maintenance therapy for small cell lung cancer (SCLC)
13. Matrix metalloproteinase inhibition: a review of anti-cancer agents
14. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression
15. Changing views of the role of matrix metalloproteinases in metastases
16. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients
17. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung
18. Expression of matrix metalloproteinases and their tissue inhibitors in non-small cell lung cancer
19. Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas: a molecular and immunohistochemical study
20. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small cell lung cancer
21. Tumor angiogenesis and the role of the αvβ3
22. Localization of MMP-2 on the surface of invasive cells by interaction with integrin αvβ3
23. Disruption of angiogenesis by PEX, a non-catalytic MMP fragment with integrin-binding activity
24. Expression of vascular endothelial growth factor related to 72 kilodalton metalloproteinase immunostaining with patients with serous ovarian tumors
25. Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast cancer
26. AE-941, an inhibitor of angiogenesis: rationale for development in combination with induction chemotherapy/radiotherapy in patients with non small cell lung cancer (NSCLC)
27. Cartilege as a source of natural inhibitors of angiogenesis
28. Matrix proteinase inhibition by AE-941, a multi-functional anti-angiogenic compound
29. The vascular endothelial cell growth factor family: identification of a fourth molecular species in characterization of alternative splicing of RNA
30. The biology of vascular endothelial growth factor
31. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia
32. Vascular permeability factor/vascular endothelial growth factor, microvascular permeability, and angiogenesis
33. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression
34. Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas
35. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer
36. Pulmonary adenocarcinoma angiogenesis: a study of factors that may influence tumor angiogenesis and survival
37. Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma
38. High pre-treatment level of serum vascular endothelial growth factor (VEFG) is associated with poor outcome in small-cell lung cancer
39. A randomized Phase II trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with Stage IIIb/IV NSCLC
40. A Phase II trial of single-agent rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) in patients with relapsed metastatic breast cancer
41. A randomized Phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer
42. A Phase II trial of humanized monoclonal anti-vascular endothelial growth factor antibody (rhuMAb VEGF) in hormone refractory prostate cancer (HRPC)
43. The Fms-like tyrosine kinase, a receptor for vascular and endothelial growth factor
44. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor
45. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules
46. Expression of vascular endothelial growth factor and its receptors flt and kdr in ovarian carcinoma
47. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/kdr) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types
48. Phase 1 dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies
49. Thalidomide is an inhibitor of angiogenesis
50. A Phase II study of thalidomide for Kaposi's Sarcoma: activity and correlation with KSHV DNA load
51. Phase 1/2 study of carboplatin and thalidomide in recurrent glioblastoma multiforme
52. Pilot and safety trial of carboplatin, paclitaxel and thalidomide in advanced non-small cell lung cancer
53. Endostatin: an endogenesis inhibitor of angiogenesis and tumor growth
54. Oncogenic ras fails to restore an in vivo tumorigenic phenotype in embryonic stem cells lacking vascular endothelial growth factor (VEGF)
55. Inhibitors of protein prenylation inhibit glioma and endothelial cell proliferations
56. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor